Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy

BACKGROUND: Risk of pneumocystosis after discontinuation of primary or secondary prophylaxis among HIV-infected patients before CD4 counts increase to ≧200 cells/μL (early discontinuation) after receiving highly active antiretroviral therapy (HAART) is rarely investigated. METHODS: Medical records o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Chien-Yu, Chen, Mao-Yuan, Hsieh, Szu-Min, Sheng, Wang-Huei, Sun, Hsin-Yun, Lo, Yi-Chun, Liu, Wen-Chun, Hung, Chien-Ching
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885390/
https://www.ncbi.nlm.nih.gov/pubmed/20492660
http://dx.doi.org/10.1186/1471-2334-10-126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885390/
https://www.ncbi.nlm.nih.gov/pubmed/20492660
http://dx.doi.org/10.1186/1471-2334-10-126

Ejemplares similares